The largest database of trusted experimental protocols

8 protocols using sb202190

1

Inhibition of Immune Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
LA-4 cells were pre-incubated with the indicated amounts of either the mTOR inhibitor rapamycin (Invivogen, Toulouse, France), MAPK-inhibitors U0126 (MEK1/2 MAPK inhibitor, Cell Signaling Technologies, Leiden, The Netherlands), SP600125 (SAP/JNK MAPK inhibitor, Invivogen), SB-202190 (p38α/β MAPK inhibitor, Invivogen), the NFκB- and MAPK-inhibitor dexamethasone (Invivogen), the IKK-β-inhibitor TPCA-1 (Abcam, Berlin, Germany), the inhibitor of actin polymerization cytochalasin A (Sigma-Aldrich), the inhibitor of endosomal acidification chloroquine (InvivoGen), or the COX2-inhibitor NS-398 (Sigma-Aldrich, Steinheim, Germany) for 90 min and subsequently stimulated with rFlaA:Betv1 for 24 h. For analyzing cell viability, LA-4 cells were treated as indicated and stained for dead cells using the fixable viability dye eFlour450 (#65-0865-14, eBioscience) and measured by FACS. Data were analyzed using FlowJo V.7 (Treestar Inc., Ashland, OR, USA) and GraphPad PRISM (GraphPad Software, San Diego, CA, USA).
+ Open protocol
+ Expand
2

Signaling Pathways in rFlaA:Betv1 BMDM Activation

Check if the same lab product or an alternative is used in the 5 most similar protocols
To analyze signaling pathways involved in rFlaA:Betv1-mediated BMDM activation, BMDMs were pre-incubated with the indicated amounts of rapamycin (mTOR inhibitor) or the respective MAPK inhibitors, including either SP600125 (SAP/JNK MAPK inhibitor), SB-202190 (p38α/β MAPK inhibitor, all Invivogen, Toulouse, France), or U0126 (MEK1/2 MAPK inhibitor, Cell Signaling Technologies, Leiden, The Netherlands) for 90 min and subsequently stimulated with rFlaA:Betv1 for either 24 h (ELISA) or 96 h (ELISA and analysis of cell metabolic state).
+ Open protocol
+ Expand
3

Inhibiting Immune Response Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
For inhibition experiments mDCs were pre-incubated with the indicated amounts of rapamycin (mTOR inhibitor), BAY-11-7082 (irreversible inhibitor of TNF-α-induced IkB-α phosphorylation resulting in inactivation of NFkB), triptolide (NFκB inhibitor), dexamethason (NFκB and MAPK inhibitor), the IKK-β inhibitors TPCA-1 (Abcam, Cambridge, UK) and BMS-345541 (Abcam, Cambridge, UK), as well as the MAPK inhibitors SP600125 (JNK MAPK inhibitor, Invivogen, Toulouse, France), SB-202190 (p38α/β MAPK inhibitor, Invivogen, Toulouse, France), or U0126 (MEK1/2 MAPK inhibitor, Cell Signaling Technologies, Leiden, The Netherlands) for 90 min and subsequently stimulated with equimolar amounts of rFlaA + rBet v 1 or rFlaA:Betv1 for either 30 min (Western Blot), 24 h (ELISA and cytotoxicity), or 72 h (ELISA and analysis of cell metabolic state). Toxicity of the used inhibitors was determined using the fixable viability dye eFlour780 (Thermo Fisher Scientific, Darmstadt, Germany, Repository Figure S1). Inhibitor concentrations showing toxic effects were excluded from the analysis.
+ Open protocol
+ Expand
4

Listeria Monocytogenes Infection Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human C5a and C3a were purchased from Complement Technology. The C5aR agonist (C5aA) (RAARISLGPRSIKAFTE) (29 (link)) and C3aR agonist (C3aA) (WWTRRWRGDKLGLAR) (30 (link)) were synthesized by GenScript with greater than 95% purity. c-di-AMP, BX795, Wortmannin, U0126, and SB202190 were purchased from Invivogen. LPS from E. coli was purchased from List Labs, and CGI-1746 was purchased from ApexBio. Listeria monocytogenes ATCC strain 13932 (serotype 4b) (MicroBioLogics, Inc.) was used for the infection studies. Bacteria were cultured in Bacto brain heart infusion broth at 37°C to mid-logarithmic phase, harvested by centrifugation, washed once in sterile PBS, and resuspended in sterile PBS.
+ Open protocol
+ Expand
5

Inhibition of Inflammatory Pathways in THP-1 Macrophages

Check if the same lab product or an alternative is used in the 5 most similar protocols
PMA-differentiated, THP-1 macrophages were pre-incubated with the indicated amounts of either the IKK-β inhibitors TPCA-1 (Abcam, Cambridge, UK) or BMS-345541 (Abcam), the unspecific inflammasome inhibitor VX-765 (InvivoGen), which inhibits caspase-1 activity, the specific NLRP3-inflammasome inhibitor MCC950 (InvivoGen), or the MAPK inhibitors SP600125 (SAP/JNK MAPK inhibitor, InvivoGen), SB202190 (p38α/β MAPK inhibitor, InvivoGen), or U0126 (ERK MAPK inhibitor, Cell Signaling Technologies, Leiden, The Netherlands) for 90 min and subsequently stimulated with rFlaA:Betv1 for 24 h. The target molecules of the used inhibitors are summarized in Supplementary Figure 2. For viability analysis, cells were treated as indicated, stained for dead cells using the fixable viability dye eFlour780 (#65-0865-14, eBioscience), and measured using a BD LSRFortessa™ flow cytometer (BD Biosciences). Data were analyzed using FlowJo V.7 (Treestar Inc., Ashland, OR, USA) and GraphPad PRISM (GraphPad Software, San Diego, California, USA).
+ Open protocol
+ Expand
6

oxPt Sensitivity in Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
HEK293 Flp pFRT/eGFP was a gift from Jacob Giehm Mikkelsen, Aarhus University, while CRC cells originated from the ATCC and NCI-60 repositories (kind gift from Nils Brünner, University of Copenhagen). The cell lines were authenticated by our in-house STR analysis (http://identicell.dk), and were tested negative for mycoplasma using MycoSensor PCR Assay Kit (Stratagene). All the cell lines were grown in RPMI medium 1640 with L-glutamine (Life Technologies) supplemented with 10% heat-inactivated fetal calf serum (Life Technologies). The cells were propagated in 37 °C at 90% air humidity and with 5% CO2. For oxPt treatment cells were first induced for 48 or 72 h with 50 ng ml−1 doxycycline hyclate (Sigma-Aldrich), and then cultured in medium supplemented with the indicated concentrations of oxPt (Fresenius Kabi) together with doxycycline. Chemical inhibitors SB203580 (Invivogen) and SB202190 (Invivogen) were dissolved in dimethyl sulphoxide (DMSO) and kept in aliquots at −20 °C until use. The cells were pre-incubated 1 h with inhibitor (or DMSO) supplemented medium before exposure to oxPt (or medium) containing inhibitor (or DMSO).
+ Open protocol
+ Expand
7

Isolation and Culture of Murine Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
B cells and naïve CD4+ T cells were isolated from mouse spleen using mouse B cell and naïve T cell isolation kits (Miltenyi Biotech) according to previously published optimized protocols 30 , 31 . NIH3T3 mouse fibroblast cell line (ATCC CRL-1658) was provided by O. Voss. Phoenix Eco retroviral packaging cell line (ATCC CRL-3214) was purchased from American Type Culture Collection (ATCC). All cells were maintained in RPMI 1640 media supplemented with 50 μM 2-mercaptoethanol, 50 U/ml penicillin, 50 μM streptomycin, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 10 mM HEPES unless otherwise specified. The pathway inhibitors SP600125, PD98059, Wortmannin, Rapamycin, SB202190 were purchased from Invivogen. MHY1485 and Akt Inhibitor IV (Akt IV) were purchased from Sigma-Aldrich.
+ Open protocol
+ Expand
8

Isolation and Culture of Murine Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
B cells and naïve CD4+ T cells were isolated from mouse spleen using mouse B cell and naïve T cell isolation kits (Miltenyi Biotech) according to previously published optimized protocols 30 , 31 . NIH3T3 mouse fibroblast cell line (ATCC CRL-1658) was provided by O. Voss. Phoenix Eco retroviral packaging cell line (ATCC CRL-3214) was purchased from American Type Culture Collection (ATCC). All cells were maintained in RPMI 1640 media supplemented with 50 μM 2-mercaptoethanol, 50 U/ml penicillin, 50 μM streptomycin, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 10 mM HEPES unless otherwise specified. The pathway inhibitors SP600125, PD98059, Wortmannin, Rapamycin, SB202190 were purchased from Invivogen. MHY1485 and Akt Inhibitor IV (Akt IV) were purchased from Sigma-Aldrich.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!